Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TYMS | P04818 | 6/20 | 0.56 |
| ▸ | LMNA | P02545 | 1/20 | 0.56 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.56 |
| ▸ | TYMP | P19971 | 2/20 | 0.52 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3341208 | 1.00 | TYMS (0.56) | TYMSLMNASMN1; SMN2TYMPHSP90AA1 | |
| SCHEMBL7703578 | 1.00 | TYMS (0.56) | TYMSLMNASMN1; SMN2TYMPHSP90AA1 | |
| SCHEMBL3341212 | 1.00 | TYMS (0.56) | TYMSLMNASMN1; SMN2TYMPHSP90AA1 | |
| SCHEMBL8326876 | 0.93 | LMNA (0.64) | TYMSLMNASMN1; SMN2TYMPHSP90AA1 | |
| SCHEMBL8326880 | 0.93 | LMNA (0.64) | TYMSLMNASMN1; SMN2TYMPHSP90AA1 | |
| SCHEMBL23517951 | 0.91 | TYMS (0.56) | TYMSTYMP | |
| SCHEMBL22983972 | 0.91 | TYMS (0.56) | TYMSTYMP | |
| SCHEMBL22983968 | 0.91 | TYMS (0.56) | TYMSTYMP | |
| SCHEMBL2460807 | 0.91 | TYMS (0.56) | TYMSTYMP | |
| SCHEMBL14064188 | 0.91 | TYMS (0.56) | TYMSTYMP |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-5741900-A | REACTING PROTECTED FLUOROURIDINE WITH SUCCINIC ANHYDRIDE, ATTACHING TO LONG-CHAIN ALKYLAMINE CONTROLLED PORE GLASS IN ANHYDROUS PYRIDINE IN PRESENCE OF DIMETHYLAMINOPYRIDINE AND DIMETHYLAMINOPROPYL/ETHYLCARBODIIMIDE | THE BOARD OF REGENTS OF THE UNIVERSITY OF NEBRASKA (US) | 1998-04-21 | — | — | US | claimed |
| US-20250145654-A1 | COMPOUNDS AND METHODS FOR TREATING DISEASE | ROME THERAPEUTICS, INC. | 2025-05-08 | — | — | US | disclosed |
| EP-4493573-A1 | COMPOUNDS AND METHODS FOR TREATING DISEASE | Rome Therapeutics, Inc. (US) | 2025-01-22 | — | — | EP | disclosed |
| US-12187758-B2 | Compounds and methods for treating disease | ROME THERAPEUTICS, INC. (US) | 2025-01-07 | — | — | US | disclosed |
| WO-2024103016-A1 | 4'-HALOMETHYL-CYTIDINE PHOSPHORAMIDATES AND RELATED COMPOUNDS AND THEIR USE IN TREATING MEDICAL CONDITIONS | ROME THERAPEUTICS, INC. (US) | 2024-05-16 | — | — | WO | disclosed |
| US-20230374058-A1 | COMPOUNDS AND METHODS FOR TREATING DISEASE | ROME THERAPEUTICS, INC. | 2023-11-23 | — | — | US | disclosed |
| WO-2023178133-A9 | COMPOUNDS AND METHODS FOR TREATING DISEASE | ROME THERAPEUTICS, INC. (US) | 2023-10-26 | — | — | WO | disclosed |
| WO-2023178133-A1 | COMPOUNDS AND METHODS FOR TREATING DISEASE | ROME THERAPEUTICS, INC. (US) | 2023-09-21 | — | — | WO | disclosed |
| US-20230295212-A1 | COMPOUNDS AND METHODS FOR TREATING DISEASE | ROME THERAPEUTICS INC (US) | 2023-09-21 | — | — | US | disclosed |
| US-6342485-B1 | ANTITUMOR AGENTS WITH NUCLEIC ACIDS | GMEINER, WILLIAM H. | 2002-01-29 | — | — | US | disclosed |
| US-5741900-A | REACTING PROTECTED FLUOROURIDINE WITH SUCCINIC ANHYDRIDE, ATTACHING TO LONG-CHAIN ALKYLAMINE CONTROLLED PORE GLASS IN ANHYDROUS PYRIDINE IN PRESENCE OF DIMETHYLAMINOPYRIDINE AND DIMETHYLAMINOPROPYL/ETHYLCARBODIIMIDE | THE BOARD OF REGENTS OF THE UNIVERSITY OF NEBRASKA (US) | 1998-04-21 | — | — | US | disclosed |
| US-5663321-A | INHIBITOR OF THYMIDYLATE SYNTHASE; ANTICANCER/ANTITUMOR AGENTS | THE BOARD OF REGENTS OF THE UNIVERSITY OF NEBRASKA (US) | 1997-09-02 | — | — | US | disclosed |
| US-5614505-A | 5-FLUOROURIDINE OR 5-FLUORODEOXYURIDINE, DRUG DELIVERY, IMPROVED BIOAVAILABILITY, ANTICARCINOGENIC AGENTS | THE BOARD OF REGENTS OF THE UNIVERSITY OF NEBRASKA (US) | 1997-03-25 | — | — | US | disclosed |
| US-5457187-A | Antitumor, anticarcinogeic agents | BOARD OF REGENTS UNIVERSITY OF NEBRASKA (US) | 1995-10-10 | — | — | US | disclosed |
| WO-1992014758-A1 | CONJUGATE MOLECULES | THE AUSTIN RESEARCH INSTITUTE (AU) | 1992-09-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230295212-A1 | COMPOUNDS AND METHODS FOR TREATING DISEASE | EHMT1, POLRMT, RNASE1 | TYMS 239/4885LMNA 2032/4885SMN1; SMN2 152/4885 |
| US-20230374058-A1 | COMPOUNDS AND METHODS FOR TREATING DISEASE | EHMT1, POLRMT, RNASE1 | TYMS 239/4885LMNA 2032/4885SMN1; SMN2 152/4885 |
| US-20250145654-A1 | COMPOUNDS AND METHODS FOR TREATING DISEASE | EHMT1, POLRMT, RNASE1 | TYMS 239/4885LMNA 2032/4885SMN1; SMN2 152/4885 |
| US-12187758-B2 | Compounds and methods for treating disease | EHMT1, POLRMT, RNASE1 | TYMS 239/4885LMNA 2032/4885SMN1; SMN2 152/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.